For those who did not know it yet:
Some drugs, like GLP-1 (for diabetes and weight loss), are very popular but are tightly controlled by the FDA to ensure their safety and high quality.
However, there is a loophole in the law called the 503A exemption, which allows pharmacies to make customized versions of these drugs for individual patients on a doctor's prescription. This means that companies like $HIMS (-15,45%) could potentially sell these drugs without having to go through the usual rigorous FDA approval process.
If they do this, it could be a smart way to meet the huge demand for these treatments.
$HIMS (-15,45%) is now promoting personalized GLP-1 because it allows them to avoid the shortage regulations.
As long as a doctor prescribes a personalized prescription that is not available on the market, that prescription can be sold whether there is a shortage or not. (503A)
